NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-17-045 from the NIH Guide for Grants and Contracts. This initiative will support projects that focus solely on development of technologies with the potential to enable biomedical research. Projects should be justified in terms of potential biomedical impact, but should not include any application to specific biomedical research questions.
Funding Opportunity PAR-17-046 from the NIH Guide for Grants and Contracts. This initiative will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high risk approaches with potential for significant impact. Projects will entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, and should not be included. Preliminary data demonstrating feasibility of the proposed approach indicates that the project is beyond the scope of this program and therefore unsuitable for this funding opportunity.
Funding Opportunity PA-17-043 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to develop and implement effective interventions to address health disparities among U.S. immigrant populations.
Funding Opportunity PA-17-044 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate innovative exploratory and developmental research to develop and test feasibility of effective interventions to address health disparities among U.S. immigrant populations.
Notice NOT-HD-16-031 from the NIH Guide for Grants and Contracts
Notice NOT-HD-16-032 from the NIH Guide for Grants and Contracts
Notice NOT-AR-17-014 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-041 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.
Funding Opportunity PA-17-042 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory and developmental research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations
Funding Opportunity RFA-AG-18-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support an initial series of activities over a 3-year period to build the foundation for enhanced collaborations across NIA's 6 centers programs. These collaborations are intended to leverage NIA's substantial investments by fostering the development of novel interdisciplinary efforts in aging research. This opportunity will provide resources to build additional infrastructure and establish specific collaborative activities that could include, but are not limited to, information and data exchange, meetings and conferences, pilot studies, research opportunities for beginning investigators, visiting scholar programs, dissemination, and other collaborative efforts. The successful awardee will involve all 6 centers programs.
Funding Opportunity PAR-17-040 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities that enhance the diversity of the biomedical workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences and courses for skills development.
Funding Opportunity PAR-17-037 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
Funding Opportunity PAR-17-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
Funding Opportunity RFA-AG-17-059 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and related dementia (ADRD). Studies may be observational treatment studies or pragmatic clinical trials. This FOA will support pilot research to test the feasibility of interventions (R21 phase) that, if successful, can transition to an R33 phase for implementation of pragmatic trials. The transition from the R21 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the criteria that are specified in the R21 phase.
Funding Opportunity RFA-AG-17-060 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and related dementia (ADRD). This FOA will support advanced-stage observational treatment studies or pragmatic clinical trials.
Funding Opportunity RFA-ES-17-002 from the NIH Guide for Grants and Contracts. The purpose of the ViCTER program is to foster and promote transdisciplinary collaborations and/or translational research efforts among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers and other individuals with expertise relevant to environmental health who have come together in common interest around a particular environmental stressor(s) of interest. A key component of the Virtual Consortia Program is the stimulation of innovative and novel cross-disciplinary and/or translational collaborations that can be more difficult to achieve in a typical R01 application, thereby accelerating the public health impact of the research.
Notice NOT-HL-16-459 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-16-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to initiate and implement a network of participating clinical centers to perform pilot and feasibility studies of therapies to slow or reverse the progression of chronic kidney disease (CKD) in children. This FOA invites applications for the Participating Clinical Centers (PCCs) and runs in parallel with a separate FOA that invites applications for the Data Coordinating Center (DCC) (RFA-DK-16-035). These pilot studies will seek to optimize critical elements of a full-scale randomized control trial design - the most promising study question, agent(s), target population, dosing, data collection, and appropriate outcomes. Applicants must propose two trials to be conducted sequentially over the funding period. One trial will be to lower serum uric acid levels, while the other can be an appropriately justified study question of the applicant's choosing. When applicable, clinical site investigators may enlist industry collaboration to achieve the goals of the network. The ultimate goal of this FOA is to obtain the necessary information to design and implement one or more full-scale randomized controlled clinical trials of therapies to reduce morbidity in children with CKD.
Funding Opportunity RFA-DK-16-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to initiate and implement a network of participating clinical centers and a data coordinating center to perform pilot and feasibility studies of therapies to slow or reverse the progression of chronic kidney disease (CKD) in children. This FOA invites applications for the Data Coordinating Center (DCC) and runs in parallel with a separate FOA that invites applications for the Participating Clinical Centers (PCCs) (RFA-DK-16-018). These pilot studies will seek to optimize critical elements of a full-scale randomized control trial design - the most promising study question, agent(s), target population, dosing, data collection, and appropriate outcomes. Applicants must propose two trial designs to be conducted sequentially over the funding period. One trial will be to lower serum uric acid levels, while the other can be an appropriately justified study question of the applicant's choosing. The ultimate goal of this FOA is to obtain the necessary information to design and implement one or more full-scale randomized controlled clinical trial of therapies to reduce morbidity in children with CKD.
Funding Opportunity PAR-17-035 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.